Results 311 to 320 of about 288,435 (354)

Advanced conjunctival melanoma

Canadian Journal of Ophthalmology, 2004
Conjunctival melanoma is a rare neoplasm with an aggressive behaviour characterized by a high tendency to develop recurrences and metastases. The authors describe the clinicopathological features of four Mexican patients with advanced conjunctival melanoma.Review of the cases of four patients with advanced conjunctival melanoma seen at an ...
Abelardo A, Rodríguez-Reyes, Dolores, Ríos y Valles-Valles, Sonia, Corredor-Casas, Alfredo, Gómez-Leal   +3 more
openaire   +2 more sources

Biochemotherapy for advanced melanoma

Critical Reviews in Oncology/Hematology, 2002
The combination of cisplatin-based chemotherapy with interleukin-2 and interferon-alpha, referred to as biochemotherapy or chemoimmunotherapy, has shown promising antitumor activity in patients with metastatic melanoma. Phase II studies have reported overall response rates ranging from 40 to 60%, with durable complete remissions in approximately 10% of
Ulrich, Keilholz, Martin E, Gore
openaire   +4 more sources

THERAPEUTIC ADVANCES IN MELANOMA

Dermatologic Clinics, 2000
Therapy for melanoma continues to evolve, and with the expanding work in the basic pathophysiology, the continued development of biologic modifiers is expected. With new treatment regimens, the rate of remissions is improving for patients with metastatic disease.
J M, Pitts, M E, Maloney
openaire   +2 more sources

Advances in cutaneous melanoma

Clinical and Translational Oncology, 2012
After several decades of slow progress in the field of melanoma, significant advances have been reported in recent years. These include a better understanding of the molecular biology of the tumour, a new staging classification system, insights into the patterns of relapse in early stage, and new drugs for the treatment of advanced disease.
Enrique, Espinosa, Alfonso, Berrocal, José Antonio, López Martín, María, González Cao, Pablo, Cerezuela, José Ignacio, Mayordomo, Salvador, Martín Algarra   +6 more
openaire   +2 more sources

Recent Advances in Melanoma Tumorigenesis

Journal of Drugs in Dermatology, 2022
Melanoma is a tumor that continues to increase in both the number of cases presenting and mortality. Patients with disease that has spread beyond the cutaneous boundary still suffer from significant morbidity and mortality despite advances in immune therapy.
Michael, Bernhardt, Aaron, Bernhardt
openaire   +2 more sources

Advances in melanoma therapy

Journal of the American Academy of Dermatology, 1998
This review discusses several advances in melanoma therapy that have recently occurred or are presently in a developmental stage. We discuss the history and present dogma regarding assessment of the regional lymph nodes and adjuvant therapy for melanoma.
T M, Johnson, A M, Yahanda, A E, Chang, D J, Fader, V K, Sondak   +4 more
openaire   +2 more sources

Vaccines against advanced melanoma

Clinics in Dermatology, 2013
Research shows that cancers are recognized by the immune system but that the immune recognition of tumors does not uniformly result in tumor rejection or regression. Quantitating the success or failure of the immune system in tumor elimination is difficult because we do not really know the total numbers of encounters of the immune system with the ...
Tatiana, Blanchard, Pramod K, Srivastava, Fei, Duan   +2 more
openaire   +2 more sources

Research progress in advanced melanoma

Cancer Letters, 2017
Melanoma is a malignant tumor with high rate of metastasis and poor prognosis. How melanoma develops and how to treat it will continue to be a hot topic. This review briefly summarizes the mechanism of melanoma development and the latest progress in its treatment.
Cong, Luo, Jiayu, Shen
openaire   +2 more sources

Chemotherapy for advanced malignant melanoma

International Journal of Clinical & Laboratory Research, 1992
Systemic chemotherapy for the treatment of metastatic melanoma remains disappointing. Nor new single agent has demonstrated promising results. The combination of cisplatin, decarbazine, carmustine, and tamoxifen appears to be one of the most active regimens with an overall response rate approaching 50%. In some patients, responses have been durable and
A C, Buzaid, J, Murren
openaire   +2 more sources

Adoptive Immunotherapy of Advanced Melanoma

Current Treatment Options in Oncology, 2012
Adoptive cell therapy (ACT) has emerged as an effective therapy for patients with metastatic melanoma. Since the first introduction of the protocol in 1988 [1], major improvements have been achieved with response rates of 40%-72% among patients who were resistant to previous treatment lines.
Ronnie, Shapira-Frommer, Jacob, Schachter   +1 more
openaire   +2 more sources